RESERVED AREA     |

Archive for tag: COST Action

Future MINDDS

cropped-mindds-cost-action.png

MINDDS will come to the end of its COST Action status and funding on May 6th 2022. We all would like to thank the COST Association for supporting us over the la...

Read More

MINDDS in Solidarity

mindds

MINDDS and all other COST Actions are deeply saddened by the ongoing conflict in Ukraine, and wherever possible wishes to help support our displaced Ukrainian r...

Read More

Cardiff MINDDS Conference – today and beyond!

mindds-news

The first MINDDS COST Action Workshop was held just over 4 years ago in Belgrade, Serbia. Despite the challenges of a global pandemic and local political events...

Read More

14th Troina Meeting on Genetics of Neurodevelopmental Disorders

2019_REPORT COST_Troina Meeting_1

Meeting: 14th Troina Meeting on Genetics of Neurodevelopmental Disorders, April 4th-6th, 2019 Participant: Natália Oliva Teles – Management Committee Member (Su...

Read More

16p11.2: rare genetic changes linked to autism now connected to higher chance of other psychiatric disorders

file-20190227-150688-e8d7t5 (1)

In most of the trillion cells that make up our bodies, 23 pairs of chromosomes store the vital strands of DNA needed to make our bodies grow and function proper...

Read More

MINDDS Newsletter August 2018

mindds-img-web-5

The summer is here !, but we have still been busy with MINDDS through the last few months, building on our progress at the end of last year. To recap, we have ...

Read More

A Meeting of MINDDS

mindds-meeting

Mental Health is one of today’s great challenges. For the young generations, the Neurodevelopmental disorders (NDD) are some of the most common, but also the mo...

Read More

Academia Europaea – International networks: creating opportunities for collaborative research and funding

mindds-news-academia-europea

(from left to right): Prof Ole Petersen, Prof Sierd Cloetingh, Prof Adrian Harwood, Abdul Rahim, Prof Phil Jones and Sir John Skehel Professor Sierd Cloetingh, ...

Read More

MINDDS

Understanding rare neurodevelopmental disorders (NDD) has the potential drive major new therapies for the common NDD of schizophrenia and Autism Spectrum Disorder (ASD).